Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study
Policosanol is a cholesterol-lowering drug with concomitant antiplatelet effects. The present study was undertaken to compare the effects of policosanol and lovastatin on patients with moderately severe intermittent claudication. The study had a 4-week baseline step, followed by a 20-week double bli...
Gespeichert in:
| Veröffentlicht in: | Angiology 2003-01, Vol.54 (1), p.25-38 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | 1 |
| container_start_page | 25 |
| container_title | Angiology |
| container_volume | 54 |
| creator | Castaño, Gladys Más, Rosa Fernández, Lilia Gámez, Rafael Illnait, José |
| description | Policosanol is a cholesterol-lowering drug with concomitant antiplatelet effects. The present study was undertaken to compare the effects of policosanol and lovastatin on patients with moderately severe intermittent claudication. The study had a 4-week baseline step, followed by a 20-week double blinded, randomized treatment period. Twenty-eight patients who met study entry criteria were randomized to policosanol 10 mg or lovastatin 20 mg tablets once daily. Walking distances in a treadmill (constant speed 3.2 km/hr, slope 10°, temperature 25°C) were assessed before and after 20 weeks of treatment. Both groups were similar at random ization. Compared with baseline, policosanol increased significantly (p |
| doi_str_mv | 10.1177/000331970305400104 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_224695010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A98080313</galeid><sage_id>10.1177_000331970305400104</sage_id><sourcerecordid>A98080313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-cb937cc9d9aff89ee2fc3ecdd5a12e6ceeede0d2b4ba1d9265d973eaee6b0e263</originalsourceid><addsrcrecordid>eNp90d1rUzEUAPAgiqub_4APEgTfvFs-7kfjW1enGxRWUJ8vuclJzchNapI73X9vSgsVLJJAvn4nIecg9IaSS0q77ooQwjkVHeGkqQmhpH6GZlTUpKJNVz9Hsx2oduIMvUrpoSwbStqX6IyyRvBa8Bn6fWMMqJxwMHgdnFUhSR8cll7jVXiUKctsPS59XSbgi_xl8w985zPE0eZctvDSyUlbVUDwH_ECfwrT4KC6drbcsgzjVsZy9gh4bV3I-Gue9NMFemGkS_D6MJ6j759vvi1vq9X9l7vlYlWpuu1ypQbBO6WEFtKYuQBgRnFQWjeSMmgVAGggmg31IKkWrG206DhIgHYgwFp-jt7t793G8HOClPuHMEVfnuwZq1vRlLwd0UY66K03IUepRptUvxBzMiec8oI-nEAb8BClCx6MLdt_8-oEL03DWNJ8wrO9VzGkFMH022hHGZ96Svpdvft_612C3h5-Nw0j6GPIocAFvD8AmZR0JkqvbDq6umEdofPirvYuyQ0cU_Sfp_8ArCzANg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224695010</pqid></control><display><type>article</type><title>Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Castaño, Gladys ; Más, Rosa ; Fernández, Lilia ; Gámez, Rafael ; Illnait, José</creator><creatorcontrib>Castaño, Gladys ; Más, Rosa ; Fernández, Lilia ; Gámez, Rafael ; Illnait, José</creatorcontrib><description><![CDATA[Policosanol is a cholesterol-lowering drug with concomitant antiplatelet effects. The present study was undertaken to compare the effects of policosanol and lovastatin on patients with moderately severe intermittent claudication. The study had a 4-week baseline step, followed by a 20-week double blinded, randomized treatment period. Twenty-eight patients who met study entry criteria were randomized to policosanol 10 mg or lovastatin 20 mg tablets once daily. Walking distances in a treadmill (constant speed 3.2 km/hr, slope 10°, temperature 25°C) were assessed before and after 20 weeks of treatment. Both groups were similar at random ization. Compared with baseline, policosanol increased significantly (p<0.01) the initial claudi cation distance (ICD) from 160.39 ±15.82 m to 211.31 ±21.48 m (+33.7%) and the absolute claudication distance (ACD) (p<0.001) from 236.39 ±25.44 m to 288.09 ±28.47 m (+24.3%); meanwhile both variables remained unchanged after lovastatin therapy. Changes in ICD and ACD were significantly larger in the policosanol than in the lovastatin group (p<0.01). Policosanol, but not lovastatin, significantly increased (p < 0.05) the ankle/arm index, although between-group differences were not significant. The frequency of patients reporting improve ment on quality of life domains was greater in the policosanol than in the lovastatin group. Policosanol significantly (p< 0.00 1 ) lowered total cholesterol (TC) and low-density lipoprotein- cholesterol (LDL-C) by 17.5% and 31.0%, respectively, and meanwhile increased (p<0.01) high- density lipoprotein-cholesterol (HDL-C) levels by 31.5%. Lovastatin reduced (p<0.01) TC (18.0%), LDL-C (22.6%), and (p<0.05) triglycerides (9.8%). In addition, policosanol, but not lovastatin, moderately, but significantly, reduced (p < 0.05) fibrinogen levels, so that final values and percent changes in both groups were different (p<0.01). Treatments were well tolerated. Only 1 lovastatin patient withdrew from the study because of a nonfatal myocardial infarction. Five lovastatin patients, but none from the policosanol group, experienced 6 adverse events (AE) (p<0.01). The present results indicate that policosanol, but not lovastatin, is a suitable alternative to manage patients with intermittent claudication because of pleiotropic properties beyond its cholesterol-lowering effects.]]></description><identifier>ISSN: 0003-3197</identifier><identifier>EISSN: 1940-1574</identifier><identifier>DOI: 10.1177/000331970305400104</identifier><identifier>PMID: 12593493</identifier><identifier>CODEN: ANGIAB</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Double-Blind Method ; Fatty Alcohols - therapeutic use ; Female ; General and cellular metabolism. Vitamins ; Heart diseases ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Intermittent Claudication - drug therapy ; Intermittent Claudication - physiopathology ; Lovastatin - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pilot Projects ; Platelet Aggregation Inhibitors - therapeutic use ; Policosanol ; Severity of Illness Index ; Time Factors ; Walking - physiology</subject><ispartof>Angiology, 2003-01, Vol.54 (1), p.25-38</ispartof><rights>2003 INIST-CNRS</rights><rights>COPYRIGHT 2003 Sage Publications, Inc.</rights><rights>Copyright Westminster Publications, Inc. Jan/Feb 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-cb937cc9d9aff89ee2fc3ecdd5a12e6ceeede0d2b4ba1d9265d973eaee6b0e263</citedby><cites>FETCH-LOGICAL-c467t-cb937cc9d9aff89ee2fc3ecdd5a12e6ceeede0d2b4ba1d9265d973eaee6b0e263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/000331970305400104$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/000331970305400104$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,4010,21798,27900,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14527018$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12593493$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castaño, Gladys</creatorcontrib><creatorcontrib>Más, Rosa</creatorcontrib><creatorcontrib>Fernández, Lilia</creatorcontrib><creatorcontrib>Gámez, Rafael</creatorcontrib><creatorcontrib>Illnait, José</creatorcontrib><title>Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study</title><title>Angiology</title><addtitle>Angiology</addtitle><description><![CDATA[Policosanol is a cholesterol-lowering drug with concomitant antiplatelet effects. The present study was undertaken to compare the effects of policosanol and lovastatin on patients with moderately severe intermittent claudication. The study had a 4-week baseline step, followed by a 20-week double blinded, randomized treatment period. Twenty-eight patients who met study entry criteria were randomized to policosanol 10 mg or lovastatin 20 mg tablets once daily. Walking distances in a treadmill (constant speed 3.2 km/hr, slope 10°, temperature 25°C) were assessed before and after 20 weeks of treatment. Both groups were similar at random ization. Compared with baseline, policosanol increased significantly (p<0.01) the initial claudi cation distance (ICD) from 160.39 ±15.82 m to 211.31 ±21.48 m (+33.7%) and the absolute claudication distance (ACD) (p<0.001) from 236.39 ±25.44 m to 288.09 ±28.47 m (+24.3%); meanwhile both variables remained unchanged after lovastatin therapy. Changes in ICD and ACD were significantly larger in the policosanol than in the lovastatin group (p<0.01). Policosanol, but not lovastatin, significantly increased (p < 0.05) the ankle/arm index, although between-group differences were not significant. The frequency of patients reporting improve ment on quality of life domains was greater in the policosanol than in the lovastatin group. Policosanol significantly (p< 0.00 1 ) lowered total cholesterol (TC) and low-density lipoprotein- cholesterol (LDL-C) by 17.5% and 31.0%, respectively, and meanwhile increased (p<0.01) high- density lipoprotein-cholesterol (HDL-C) levels by 31.5%. Lovastatin reduced (p<0.01) TC (18.0%), LDL-C (22.6%), and (p<0.05) triglycerides (9.8%). In addition, policosanol, but not lovastatin, moderately, but significantly, reduced (p < 0.05) fibrinogen levels, so that final values and percent changes in both groups were different (p<0.01). Treatments were well tolerated. Only 1 lovastatin patient withdrew from the study because of a nonfatal myocardial infarction. Five lovastatin patients, but none from the policosanol group, experienced 6 adverse events (AE) (p<0.01). The present results indicate that policosanol, but not lovastatin, is a suitable alternative to manage patients with intermittent claudication because of pleiotropic properties beyond its cholesterol-lowering effects.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Fatty Alcohols - therapeutic use</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Intermittent Claudication - drug therapy</subject><subject>Intermittent Claudication - physiopathology</subject><subject>Lovastatin - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Policosanol</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Walking - physiology</subject><issn>0003-3197</issn><issn>1940-1574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90d1rUzEUAPAgiqub_4APEgTfvFs-7kfjW1enGxRWUJ8vuclJzchNapI73X9vSgsVLJJAvn4nIecg9IaSS0q77ooQwjkVHeGkqQmhpH6GZlTUpKJNVz9Hsx2oduIMvUrpoSwbStqX6IyyRvBa8Bn6fWMMqJxwMHgdnFUhSR8cll7jVXiUKctsPS59XSbgi_xl8w985zPE0eZctvDSyUlbVUDwH_ECfwrT4KC6drbcsgzjVsZy9gh4bV3I-Gue9NMFemGkS_D6MJ6j759vvi1vq9X9l7vlYlWpuu1ypQbBO6WEFtKYuQBgRnFQWjeSMmgVAGggmg31IKkWrG206DhIgHYgwFp-jt7t793G8HOClPuHMEVfnuwZq1vRlLwd0UY66K03IUepRptUvxBzMiec8oI-nEAb8BClCx6MLdt_8-oEL03DWNJ8wrO9VzGkFMH022hHGZ96Svpdvft_612C3h5-Nw0j6GPIocAFvD8AmZR0JkqvbDq6umEdofPirvYuyQ0cU_Sfp_8ArCzANg</recordid><startdate>200301</startdate><enddate>200301</enddate><creator>Castaño, Gladys</creator><creator>Más, Rosa</creator><creator>Fernández, Lilia</creator><creator>Gámez, Rafael</creator><creator>Illnait, José</creator><general>SAGE Publications</general><general>Westminster</general><general>Sage Publications, Inc</general><general>SAGE PUBLICATIONS, INC</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200301</creationdate><title>Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study</title><author>Castaño, Gladys ; Más, Rosa ; Fernández, Lilia ; Gámez, Rafael ; Illnait, José</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-cb937cc9d9aff89ee2fc3ecdd5a12e6ceeede0d2b4ba1d9265d973eaee6b0e263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Fatty Alcohols - therapeutic use</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Intermittent Claudication - drug therapy</topic><topic>Intermittent Claudication - physiopathology</topic><topic>Lovastatin - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Policosanol</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Walking - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castaño, Gladys</creatorcontrib><creatorcontrib>Más, Rosa</creatorcontrib><creatorcontrib>Fernández, Lilia</creatorcontrib><creatorcontrib>Gámez, Rafael</creatorcontrib><creatorcontrib>Illnait, José</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Angiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castaño, Gladys</au><au>Más, Rosa</au><au>Fernández, Lilia</au><au>Gámez, Rafael</au><au>Illnait, José</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study</atitle><jtitle>Angiology</jtitle><addtitle>Angiology</addtitle><date>2003-01</date><risdate>2003</risdate><volume>54</volume><issue>1</issue><spage>25</spage><epage>38</epage><pages>25-38</pages><issn>0003-3197</issn><eissn>1940-1574</eissn><coden>ANGIAB</coden><abstract><![CDATA[Policosanol is a cholesterol-lowering drug with concomitant antiplatelet effects. The present study was undertaken to compare the effects of policosanol and lovastatin on patients with moderately severe intermittent claudication. The study had a 4-week baseline step, followed by a 20-week double blinded, randomized treatment period. Twenty-eight patients who met study entry criteria were randomized to policosanol 10 mg or lovastatin 20 mg tablets once daily. Walking distances in a treadmill (constant speed 3.2 km/hr, slope 10°, temperature 25°C) were assessed before and after 20 weeks of treatment. Both groups were similar at random ization. Compared with baseline, policosanol increased significantly (p<0.01) the initial claudi cation distance (ICD) from 160.39 ±15.82 m to 211.31 ±21.48 m (+33.7%) and the absolute claudication distance (ACD) (p<0.001) from 236.39 ±25.44 m to 288.09 ±28.47 m (+24.3%); meanwhile both variables remained unchanged after lovastatin therapy. Changes in ICD and ACD were significantly larger in the policosanol than in the lovastatin group (p<0.01). Policosanol, but not lovastatin, significantly increased (p < 0.05) the ankle/arm index, although between-group differences were not significant. The frequency of patients reporting improve ment on quality of life domains was greater in the policosanol than in the lovastatin group. Policosanol significantly (p< 0.00 1 ) lowered total cholesterol (TC) and low-density lipoprotein- cholesterol (LDL-C) by 17.5% and 31.0%, respectively, and meanwhile increased (p<0.01) high- density lipoprotein-cholesterol (HDL-C) levels by 31.5%. Lovastatin reduced (p<0.01) TC (18.0%), LDL-C (22.6%), and (p<0.05) triglycerides (9.8%). In addition, policosanol, but not lovastatin, moderately, but significantly, reduced (p < 0.05) fibrinogen levels, so that final values and percent changes in both groups were different (p<0.01). Treatments were well tolerated. Only 1 lovastatin patient withdrew from the study because of a nonfatal myocardial infarction. Five lovastatin patients, but none from the policosanol group, experienced 6 adverse events (AE) (p<0.01). The present results indicate that policosanol, but not lovastatin, is a suitable alternative to manage patients with intermittent claudication because of pleiotropic properties beyond its cholesterol-lowering effects.]]></abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>12593493</pmid><doi>10.1177/000331970305400104</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-3197 |
| ispartof | Angiology, 2003-01, Vol.54 (1), p.25-38 |
| issn | 0003-3197 1940-1574 |
| language | eng |
| recordid | cdi_proquest_journals_224695010 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Double-Blind Method Fatty Alcohols - therapeutic use Female General and cellular metabolism. Vitamins Heart diseases Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Intermittent Claudication - drug therapy Intermittent Claudication - physiopathology Lovastatin - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Pilot Projects Platelet Aggregation Inhibitors - therapeutic use Policosanol Severity of Illness Index Time Factors Walking - physiology |
| title | Effects of Policosanol and Lovastatin in Patients with Intermittent Claudication: A Double-Blind Comparative Pilot Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A48%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Policosanol%20and%20Lovastatin%20in%20Patients%20with%20Intermittent%20Claudication:%20A%20Double-Blind%20Comparative%20Pilot%20Study&rft.jtitle=Angiology&rft.au=Casta%C3%B1o,%20Gladys&rft.date=2003-01&rft.volume=54&rft.issue=1&rft.spage=25&rft.epage=38&rft.pages=25-38&rft.issn=0003-3197&rft.eissn=1940-1574&rft.coden=ANGIAB&rft_id=info:doi/10.1177/000331970305400104&rft_dat=%3Cgale_proqu%3EA98080313%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224695010&rft_id=info:pmid/12593493&rft_galeid=A98080313&rft_sage_id=10.1177_000331970305400104&rfr_iscdi=true |